Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cancer of the Ovary Treated as 2nd Line Therapy”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Testing effectiveness (Phase 2)Study completedNCT00291837
What this trial is testing

CT-2106 for the Second Line Treatment of Ovarian Cancer

Who this might be right for
Ovarian Cancer
CTI BioPharma 40
Testing effectiveness (Phase 2)Study completedNCT00189410
What this trial is testing

Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours

Who this might be right for
Cancer of the Ovary Treated as 2nd Line TherapyMuellerian Mixed TumoursTumours of the Uterus+2 more
AGO Study Group 140
Testing effectiveness (Phase 2)Ended earlyNCT01521143
What this trial is testing

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

Who this might be right for
Epithelial Ovarian Cancer
Prima BioMed Ltd 91
Testing effectiveness (Phase 2)Study completedNCT00006227
What this trial is testing

Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Who this might be right for
Adult Type Ovarian Granulosa Cell TumorOvarian GynandroblastomaOvarian Sertoli-Leydig Cell Tumor+2 more
Gynecologic Oncology Group 31
Early research (Phase 1)Study completedNCT00003967
What this trial is testing

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group 24
Testing effectiveness (Phase 2)Study completedNCT00061308
What this trial is testing

Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer

Who this might be right for
Peritoneal CancerOvarian CancerNeoplasms, Ovarian+1 more
GlaxoSmithKline 75
Testing effectiveness (Phase 2)Study completedNCT00002671
What this trial is testing

Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
NYU Langone Health
Not applicableEnded earlyNCT07000344
What this trial is testing

Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor

Who this might be right for
Ovarian Cancer
Peking Union Medical College Hospital 5
Testing effectiveness (Phase 2)Study completedNCT00090610
What this trial is testing

Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer

Who this might be right for
Ovarian Cancer
Duke University 150
Testing effectiveness (Phase 2)Ended earlyNCT00758732
What this trial is testing

Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma

Who this might be right for
Ovarian Cancer
Hellenic Oncology Research Group 34
Early research (Phase 1)Ended earlyNCT00003380
What this trial is testing

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Large-scale testing (Phase 3)Looking for participantsNCT07225270
What this trial is testing

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

Who this might be right for
Ovarian CancerPlatinum-sensitive Ovarian CancerPSOC
Genmab 528
Testing effectiveness (Phase 2)Study completedNCT00403429
What this trial is testing

MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian Cancer
National Cancer Institute, Naples 36